Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 15/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25922278 | 0.87 | HCAR1 (0.34) | ABL1HCAR1 | |
| SCHEMBL31698068 | 0.81 | ABL1 (0.37) | ABL1ADORA2AADORA1HCAR3 | |
| SCHEMBL31698374 | 0.81 | HCAR1 (0.38) | HCAR1 | |
| SCHEMBL31698308 | 0.75 | HCAR1 (0.34) | ABL1HCAR1 | |
| SCHEMBL31698451 | 0.74 | ESR1 (0.41) | ABL1HCAR1ADORA2AADORA1HCAR3 | |
| SCHEMBL11814039 | 0.74 | ADORA2A (0.37) | ABL1ADORA2AADORA1HCAR3 | |
| SCHEMBL31698750 | 0.73 | CSNK1E (0.33) | ABL1HRH4 | |
| SCHEMBL31698989 | 0.73 | AAK1 (0.32) | ABL1 | |
| SCHEMBL31698452 | 0.73 | AR (0.41) | ABL1HCAR1 | |
| SCHEMBL31349605 | 0.73 | HCAR1 (0.33) | HCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | ABL1 3830/4885HCAR1 2434/4885ADORA2A 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.